八种单克隆抗体治疗慢性鼻窦炎伴鼻息肉的网状Meta分析
所有生物制剂均显著降低鼻息肉评分,IL-4Rα抑制剂(stapokibart、dupilumab)在嗅觉、生活质量和鼻塞改善上表现突出,安全性均与安慰剂相当。
要点
- 所有八种生物制剂均显著优于安慰剂降低鼻息肉评分。
- IL-4Rα抑制剂疗效最大且最一致,dupilumab改善SNOT-22最佳。
- 各生物制剂不良事件风险与安慰剂相当,GR1802安全性最优。
核心结论
- 所有评估的生物制剂疗效均优于安慰剂,IL-4受体α抑制剂获益最大且最一致。
- 所有治疗安全性良好,支持其用于CRSwNP的长期管理。
研究设计与样本
- 系统检索PubMed、Embase、Web of Science、CENTRAL Cochrane和MEDLINE的随机对照试验。
主要发现
- 所有生物制剂均显著降低鼻息肉评分(NPS),stapokibart排名第一。
- dupilumab和stapokibart均改善UPSIT评分,提示嗅觉功能恢复。
- dupilumab在改善SNOT-22评分方面领先,stapokibart在缓解鼻塞评分(NCS)方面最有效。
- 所有生物制剂不良事件风险与安慰剂相当,GR1802安全性最有利。
临床怎么用
- 对于CRSwNP患者,可考虑使用IL-4Rα抑制剂(如dupilumab、stapokibart)以获得最大且一致的疗效。
- 选择生物制剂时需综合评估疗效维度(鼻息肉、嗅觉、生活质量、鼻塞)及安全性差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biologics targeting key type 2 inflammatory mediators (e.g., IL-4Rα, IgE, IL-5, TSLP) represent a novel therapeutic approach for chronic rhinosinusitis with nasal polyps (CRSwNP). This network meta-analysis (NMA) aimed to compare the efficacy and safety of eight monoclonal antibodies for CRSwNP. METHODOLOGY: We systematically searched PubMed, Embase, Web of Science, CENTRAL Cochrane, and MEDLINE for randomized controlled trials (RCTs) comparing monoclonal antibodies with placebo CRSwNP. A Bayesian Network meta-analysis (NMA) was performed using the R gemtc package. RESULTS: Sixteen RCTs (n=2,034) evaluating eight monoclonal antibodies were included. All biologics significantly reduced Nasal Polyp Score (NPS); stapokibart (anti-IL-4Rα) ranked first. Both dupilumab and stapokibart improved the University of Pennsylvania Smell Identification Test (UPSIT) score, indicating a recovery of olfactory function. Dupilumab led in improving Sino-Nasal Outcome Test-22 (SNOT-22) scores, whereas stapokibart was most effective in relieving nasal congestion score (NCS). The risk of adverse events was comparable to placebo across all biologics, with GR1802 exhibiting the most favorable safety. CONCLUSIONS: All evaluated biological agents demonstrated efficacy superior to placebo, with IL-4 receptor alpha inhibitors showing the largest and most consistent benefits. All treatments exhibited favorable safety profiles, supporting their use for long-term management of CRSwNP.
引用
- Wang X, Ren P, He H, et al. Targeted biologics for chronic rhinosinusitis with nasal polyps: efficacy and safety comparison of eight monoclonal antibodies via network meta-analysis. Rhinology. 2026. PMID: 41574646. doi:10.4193/Rhin25.395
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。